<!DOCTYPE html>
<html lang="en">

<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Guggenheim Securities</title>
  <link rel="stylesheet" type="text/css" href="css/main.css">
</head>

<body>
  <div class='wrapper'>

<!-- MAIN NAVIGATION --> 
<header>

<div class='logo'>
  <a href="#landing"><img src="images/guggLogo.png" width='170' title="logo"></a>
</div>

</header>

<!-- LANDING --> 

<section class='landing'>

<section class='firstcall'>
  <p>OREXO AB</p>
  <p>ORX.SS - BUY</p>
</section>

  <h1>Taking Over Leadership of Zubsolv Salesforce Should Drive Greater Uptake</h1>

<section class='dateline'>
  <h4 id='category'>Specialty Pharmaceuticals</h4>
  <h4 id='date'>May 23, 2014</h4>
</section>

<section class='disclaimer'>
    <h4>this material is market commentary and not a research report</h4>
</section>

<section class='contributors'>
  <h3><a href='#'>Marty Mosby, Analyst</a> <span class='phone'>662 469 9595</span></h3>
  <h3><a href='#'>Mason Mosby, Associate</a>  <span class='phone'>662 469 919</span></h3>
</section>

<section class='btn-access'>
  <h2><a href='#'>Access this report</a></h2>
</section>

<section class='btn-buy'>
  <h2><a href='#'>BUY</a></h2>
</section>

<section class='content-main'>

    <h5> <span class='body-bold'>Guggenheim Securities, LLC thanks you for consideration of our equity research analysts in the Institutional Investor 2014 All-America Research Poll.</span> <span class='body-bold'><a href='#'>Request a ballot.</a></span></h5>

    <h5>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. <span class='body-bold'>Duis aute irure dolor in reprehenderit </span> in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, <span class='body-italic'>sunt in culpa qui officia deserunt mollit anim id est laborum.</span> </h5>

   <h5>• We believe WASH is poised to accelerate growth and improve its already stout profitability not only through its strong wealth management business but also through an enhanced focus on building the commercial lending platform in CT and steady expansion in its legacy RI market.</h5>

   <h5>• Asset quality has been outstanding through the recent credit cycle. Our reductions in 2014E and 2015E EPS reflect a slightly more conservative outlook on provision expense and how far the 1.1% relative loss reserve will ease. We are modeling only 14bp of provisioning in 2015.</h5>

   <h5><a href='#'>Medicare may soon require pre-authorization for CPAP (continuous positive airway pressure)</a></h5>

</section>


  <section class='disclosure'>

  <h6>This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, please telephone or email the sender and delete this message and any attachment from your system. If you are not the intended recipient you must not copy this message or attachment or disclose the contents to any other person.</h6> 

  <h6>*Assets under management, employee ownership, and number of employees are as of December 31, 2014. Assets under management include consulting services for clients whose assets are valued at approximately $36 billion.</h6>

  </section>

</section>



<!-- FOOTER -->

<!-- <article class='disclosure'>
    <h6>© 2015 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are trademarks or registered trademarks of Guggenheim Capital, LLC. *Assets under management, employee ownership, and number of employees are as of December 31, 2014. Assets under management include consulting services for clients whose assets are valued at approximately $36 billion.</h6>
</article> -->

</div> <!-- wrapper -->

</body>

</html>
